Genital herpes - How much of a public-health problem?

Lancet

Volumn 351, Issue SUPPL.3, 1998, Pages 16-18

  Mindel, Adrian ^a  

^a SYDNEY EYE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; VALACICLOVIR;

GENITAL HERPES; HUMAN; INFECTION CONTROL; LATENT PERIOD; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PUBLIC HEALTH; SERODIAGNOSIS; SEXUALLY TRANSMITTED DISEASE; SHORT SURVEY;

EID: 11544306181     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90005-8     Document Type: Article

References (34)

1. Government Statistical Service. Sexually transmitted diseases, England 1995: new cases seen at NHS genito-urinary medicine clinics. London: HM Stationery Office, 1996: 1-15.
2. Centers for Disease Control and Prevention. Genital herpes infections - United States, 1966-79. MMWR Morb Mortal Wkly Rep 1982; 31: 137-39.
3. Meheus A., Van Dyck E, Ursi JP, Ballard RC, Piot P. Aetiology of genital ulcerations in Swaziland. Sex Transm Dis 1983; 10: 33-35.
4. Cameron DW, Simonsen JM, D'Costa LJ, et al. Female to male transmission of human immunodeficiency virus type 1: risk factor for seroconversion in men. Lancet 1989; ii: 403-07.
5. Tayal SC, Pattman RS. High prevalence of herpes simplex virus type 1 in female anogenital herpes simplex in Newcastle upon Tyne 1983-1992. Int J STD AIDS 1994; 5: 359-61.
6. Corey L, Adams HG, Brown ZA, Holmes KK. Genital herpes simplex virus infections: clinical manifestations, course and complications. Ann Intern Med 1983; 98: 958-72.
7. Carney O, Ross E, Ikkos G, Mindel A. The effect of acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med 1993; 69: 457-59.
8. Whitley R. Neonatal herpes simplex virus infections. J Med Virol 1993 (suppl 1): 13-21.
9. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med 1997; 337: 509-15.
10. Mindel A, Brocklehurst P. The treatment of herpes simplex virus infections. In: Jeffries D, De Clercq E, eds. Antiviral chemotherapy. Chichester: John Wiley and Sons, 1995.
11. Sacks SL, Aoki FY, Diaz Mitoma F. Sellors J, Shafran SD, and the Canadian Famciclovir Study Group. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA 1996; 276: 44-49.
12. Spruance SL, Tyring SK, Degregorio B, Miller C, Beutner K, and the Valaciclovir HSV Study Group. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996; 156: 1729-35.
13. Thackray AM, Field HJ. Comparison of the effect of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob Agents Chemother 1996; 40: 846-51.
14. Nahmias AJ, Lee FK, Beckman-Nahmias S. Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scand J Infect Dis Suppl 1983; 69: 19-36.
15. Cowan F, Johnson AM, Ashley R, Corey L, Mindel A. Antibodies to herpes simplex virus type 2 as a serological marker of sexual lifestyle in populations. BMJ 1994; 309: 1325-29.
16. Koutsky L, Ashley R, Holmes K, et al. The frequency of unrecognised type 2 herpes simplex virus infection among women: implications for the control of genital herpes. Sex Transm Dis 1990; 17: 90-94.
17. Bassett I, Donovan B, Bodsworth NJ, et al. Herpes simplex virus type 2 infection of heterosexual men attending a sexual health centre. Med J Aust 1994; 160: 697-700.
18. Langeland N, Harr L, Mhula F. Prevalence of HSV-2 antibodies among STD clinic attenders. Int J STD AIDS 1998; 9: 104-07.
19. Corey L. The current trend in genital herpes: progression in prevention. Sex Transm Dis 1994; 21 (suppl 2): S38-44.
20. Forsgren M, Skoog E, Jeansson S, Ologsson S, Giesecke J. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1982 and 1989: implications for STD epidemiology. Int J STD AIDS 1994; 5: 113-16.
21. Gibson JJ, Hornun CA, Alexander GR, Lee FK, Potts WA, Nahmias AJ. A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis 1990; 162: 306-12.
22. Rosenthal S, Stanberry LR, Biro FM, et al. Seroprevalence of herpes simplex virus type 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 1996; 24: 135-39.
23. Huerta K, Berkelhamer S, Klein J, Ammerman S, Chang J, Prober CG. Epidemiology of herpes simplex virus type 2 infections in a highrisk adolescent population. J Adolesc Health 1996; 18: 384-86.
24. Johnson RE, Nahmias AJ, Magder LS, Lee FL, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321: 7-12.
25. Flemming DT, McQuillan GM, Johnson RE, et al. Herpes simplex in the United States 1976-1994. N Engl J Med 1997; 337: 1105-11.
26. Persson K, Månsson A, Jönsson E, Nordenfelt E. Decline of herpes simplex virus type 1 and Chlamydia trachomatis infections from 1970 to 1993 indicated by a similar change in antibody pattern. Scand J Infect Dis 1995; 27: 195-99.
27. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985; 12: 33-39.
28. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992; 116: 197-202.
29. Wald A, Zeh J, Selke S, Ashley R, Corey L. Virological characteristics of subclinical and asymptomatic and symptomatic genital herpes infections. N Engl J Med 1995; 333: 770-75.
30. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997; 99: 1092-97.
31. Ashley R, Corey L. HSV type specific antibody tests: patients are ready, are clinicians? Genitourin Med 1997; 73: 235-36.
32. Fairley I, Monteiro E. Patients attitudes to type specific serological tests in the diagnosis of genital herpes. Genitourin Med 1997; 73: 259-62
33. Smith J, Field HJ. Human herpesvirus vaccines: the current status of vaccine development. Herpes 1997; 4: 55-61.
34. Corey L, Ashley R, Sekulovich R, et al. Lack of efficacy of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition [abstr]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997; Toronto, Canada.